...
首页> 外文期刊>Future medicinal chemistry >Plasmodium kinases as targets for new-generation antimalarials
【24h】

Plasmodium kinases as targets for new-generation antimalarials

机译:疟原虫激酶作为新一代抗疟药的靶标

获取原文
获取原文并翻译 | 示例
           

摘要

There is an urgent need for the development of new antimalarial drugs with novel modes of actions. The malarial parasite, Plasmodium falciparum, has a relatively small kinome of <100 kinases, with many members exhibiting a high degree of structural divergence from their host counterparts. A number of Plasmodium kinases have recently been shown by reverse genetics to be essential for various parts of the complex parasitic life cycle, and are thus genetically validated as potential targets. Implementation of mass spectrometry-based phosphoproteomics approaches has informed on key phospho-signalling pathways in the parasite. In addition, global phenotypic screens have revealed a large number of putative protein kinase inhibitors with antimalarial potency. Taken together, these investigations point to the Plasmodium kinome as a rich source of potential new targets. In this review, we highlight recent progress made towards this goal.
机译:迫切需要开发具有新颖作用方式的新抗疟药。疟原虫恶性疟原虫具有相对较小的<100激酶激酶组,许多成员与其宿主对应物表现出高度的结构差异。最近,逆向遗传学已经证明许多疟原虫激酶对于复杂的寄生虫生命周期的各个部分都是必不可少的,因此在基因上已被证实为潜在的靶标。基于质谱的磷酸化蛋白质组学方法的实施已告知寄生虫中关键的磷酸信号通路。此外,全球表型筛选已发现大量推定的具有抗疟疾效力的蛋白激酶抑制剂。综上所述,这些研究表明疟原虫的激酶组是潜在的新靶标的丰富来源。在这篇评论中,我们重点介绍了朝着这个目标取得的最新进展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号